Halozyme Therapeutics (NASDAQ:HALO) First Quarter 2025 Results

Key Financial Results

Revenue: US$264.9m (up 35% from 1Q 2024). Net income: US$118.1m (up 54% from 1Q 2024). Profit margin: 45% (up from 39% in 1Q 2024). The increase in margin was driven by higher revenue. EPS: US$0.96 (up from US$0.60 in 1Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.NasdaqGS:HALO Earnings and Revenue Growth May 8th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Halozyme Therapeutics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 51%.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 17% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Halozyme Therapeutics that you need to take into consideration.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments